Leerink Partners analyst Geoffrey Porges trims its price target on Regeneron Pharma (NASDAQ: REGN) to $511.00 (from $530.00) but maintains ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS Change Analyst EPS View Analyst PT Change

Baird Downgrades Regeneron Pharma (REGN) to Neutral; EPS Expectations Will Be Hard to MeetAugust 5, 2016 6:44 AM Roth Keeps Regeneron (REGN) at 'Buy' Following Q2 Report; Says 'Blocking and Tackling' ContinuesAugust 4, 2016 2:55 PM Regeneron (REGN) Tops Q2 EPS by 17c; Updates FY16 ExpectationsAugust 4, 2016 6:32 AM Regeneron Reports Second Quarter 2016 Financial and Operating ResultsAugust 4, 2016 6:30 AM